ADARB1 and neoplasm: Importantly, our validation using paired tumor and adjacent non-cancerous tissues confirmed this downregulation for ADARB2 but not for ADAR or ADARB1, suggesting that ADARB2 may represent the most robust biomarker candidate in this context.